时间：2015-11-30

Dr. Ruiwen Zhang’s Laboratory at School of Pharmacy, Texas Tech University Health Sciences Center has a post-doctoral research associate position available immediately. His lab is nationally and internationally recognized for researches in cancer biology, cancer pharmacology and experimental therapeutics. The research team includes experts on cancer biology, drug discovery and development, medicinal chemistry, analytical chemistry, preclinical and clinical pharmacology, toxicology, and pharmaceutical sciences. Recent publications appear in high-impact journals (e.g., in PNAS, EMBO J, Gastroenterology, Nat Comm, Cancer Res, Clin Cancer Res, Nat Review Cancer, BBA Review Cancer, & Med Res Review, Oncogene).

Preferred Requirements: PhD in molecular biology, pharmacology, pharmaceutical sciences, or related life sciences; Strong Publications; Hands-on experience in molecular biology, genetics, genomics, and/or transgenic models; Knowledge and skills in drug discovery and/or development.

Application or Nomination: Submit at www.texastech.edu/careers/ to requestion 2944BR

TTHSC is an Equal Opportunity/Affirmative Action Institution. Minorities and women are encouraged to apply.

张瑞稳教授简介：

Current Cancer Drug Targets（癌症药靶研究最新进展）主编。著名药理学家，毒理学家，肿瘤学家。美国德克萨斯州理工大学终身教授，美国执业毒理学家（DABT），美国科学促进学会会士（AAAS Fellow）。张教授是上海医科大学（复旦大学上海医学院）的医学及毒理学博士，美国伯明翰阿拉巴马大学医学院（UAB）博士后（临床药理及药物基因组学），曾任UAB药理与毒理学、临床药理学终身教授，肿瘤药理中心实验室主任、德克萨斯州理工大学药学系主任。现任美国FDA顾问，NIH评委，为22家国际知名杂志的主编、副主编、资深编委及编委。受邀国际学术会议及世界各地学术研究机构作学术报告200余次。发表研究论文200余篇（引用8200余次，H-index 50）。